| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-12-08 | Pomalyst®/USA - Imnovid®/EU (pomalidomide) | relapsed and refractory multiple myeloma |
3b | Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-08 | SGN-CD33A | acute myeloid leukemia |
1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-12-08 | Adcetris® (brentuximab vedotin) | diffuse large B-cell lymphoma | Seattle Genetics (USA - WA) | Cancer - Oncology | |
| 2014-12-08 | Vidaza® | acute myeloid leukemia |
3 | Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-08 | Revlimid® (lenalidomide) | relapsed/refractory diffuse large B-cell lymphoma (DLBCL) |
2-3 | Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-08 | Fycompa® (perampanel) | primary generalized tonic-clonic (PGTC) seizures |
3 | Eisai (Japan) | CNS diseases - Neurological diseases |
| 2014-12-08 | filgrastim biosimilar (Neupogen®) | breast cancer patients eligible for myelosuppressive chemotherapy treatment | 3 | Sandoz (Switzerland) | Cancer - Oncology |
| 2014-12-07 | Revlimid® (lenalidomide) plus dexamethasone | multiple myeloma |
3 | Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-07 | ISIS-FXIRx, now IONIS-FXIRx | venous thrombolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery |
2 | Isis Pharmaceuticals, now Ionis Pharmaceutitcals (USA - CA) | Cardiovascular diseases |
| 2014-12-07 | MOR208 (Xmab5574) | relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) | 1-2a | Morphosys (Germany) Xencor (USA - CA) | Cancer - Oncology |
| 2014-12-06 | marizomib | multiple myeloma | preclinical | Triphase Accelerator (Canada - USA - CA) Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-06 | CTL019 - tisagenlecleucel-T | relapsed/refractory acute lymphoblastic leukemia in children and young adults |
Novartis (Switzerland) | Cancer - Oncology - Rare diseases | |
| 2014-12-06 | Blincyto™ (blinatumomab) | minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL) | 2 | Amgen (USA - CA) | Cancer - Oncology - Rare diseases |
| 2014-12-06 | Opdivo® (nivolumab) | relapsed or refractory classical Hodgkin lymphoma | 1b | BMS (USA - NY) | Cancer - Oncology - Rare diseases |
| 2014-12-06 | ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood | preclinical | Fate Therapeutics (USA - CA) | Cancer - Oncology - Hematological diseases | |
| 2014-12-06 | pacritinib | myelofibrosis |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | Cancer - Oncology | |
| 2014-12-06 | SGN-CD19A | acute lymphoblastic leukemia | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-12-06 | SGN-CD19A | non-Hodgkin lymphoma | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2014-12-04 | ARM210/S48168 | Duchenne muscular dystrophy |
1 | Armgo Pharma (USA - NY) Servier (France) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2014-12-04 | PREOB® | osteonecrosis |
3 | Bone Therapeutics (Belgium) | Bone diseases - Regenerative medicine |
